Publication |
2014
Abstract
Pomalidomie represents new and promising medication for pretreated multiple myeloma patients, including those resistant to lenalidomide and/or bortezomibe. A case report of a man in his 5.th progression of multiple myeloma is documented, with significant response to therapy with pomalidome 4mg oraly once daily in day 1-21 together with dexamethasone 40mg orally on day 1, 8, 15, 22.